JP2003026665A - 改善された味覚を有するキサンチン−およびフェナゾン−アセスルファム−ｈ−錯塩、その製造及び使用法 - Google Patents
改善された味覚を有するキサンチン−およびフェナゾン−アセスルファム−ｈ−錯塩、その製造及び使用法Info
- Publication number
- JP2003026665A JP2003026665A JP2002183006A JP2002183006A JP2003026665A JP 2003026665 A JP2003026665 A JP 2003026665A JP 2002183006 A JP2002183006 A JP 2002183006A JP 2002183006 A JP2002183006 A JP 2002183006A JP 2003026665 A JP2003026665 A JP 2003026665A
- Authority
- JP
- Japan
- Prior art keywords
- acesulfame
- phenazone
- compound
- xanthine
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000019640 taste Nutrition 0.000 title description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims abstract description 35
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical class CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000012453 solvate Substances 0.000 claims abstract description 9
- 150000002391 heterocyclic compounds Chemical class 0.000 claims abstract description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 3
- 229960001476 pentoxifylline Drugs 0.000 claims description 24
- 229960005222 phenazone Drugs 0.000 claims description 17
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 9
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229960002934 propentofylline Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000212 aminophenazone Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- ZGUHNWLPPVJTOG-UHFFFAOYSA-N 2-propyl-2h-phenazin-1-one Chemical compound C1=CC=C2N=C(C(C(CCC)C=C3)=O)C3=NC2=C1 ZGUHNWLPPVJTOG-UHFFFAOYSA-N 0.000 claims description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940120889 dipyrone Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 10
- 235000019658 bitter taste Nutrition 0.000 abstract description 6
- 239000013543 active substance Substances 0.000 abstract description 3
- 229960005164 acesulfame Drugs 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 21
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 13
- 235000003599 food sweetener Nutrition 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 7
- 229940075420 xanthine Drugs 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLXCHZCQTCBUOX-UHFFFAOYSA-N 1-prop-2-enylimidazole Chemical compound C=CCN1C=CN=C1 XLXCHZCQTCBUOX-UHFFFAOYSA-N 0.000 description 1
- ZITWSNQLWBKRBT-UHFFFAOYSA-N 2,3-dimethyl-1h-pyrazol-5-one Chemical class CC1=CC(=O)NN1C ZITWSNQLWBKRBT-UHFFFAOYSA-N 0.000 description 1
- XSYOXJHLNLGOIE-UHFFFAOYSA-N 3h-phenazin-2-one Chemical compound C1=CC=CC2=NC3=CC(=O)CC=C3N=C21 XSYOXJHLNLGOIE-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- -1 salt compounds Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Seasonings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10130504A DE10130504B4 (de) | 2001-06-25 | 2001-06-25 | Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE10130504.4 | 2001-06-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003026665A true JP2003026665A (ja) | 2003-01-29 |
| JP2003026665A5 JP2003026665A5 (enExample) | 2005-09-15 |
Family
ID=7689314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002183006A Withdrawn JP2003026665A (ja) | 2001-06-25 | 2002-06-24 | 改善された味覚を有するキサンチン−およびフェナゾン−アセスルファム−ｈ−錯塩、その製造及び使用法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6849623B2 (enExample) |
| EP (1) | EP1270573B1 (enExample) |
| JP (1) | JP2003026665A (enExample) |
| DE (2) | DE10130504B4 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956677B2 (en) * | 2005-11-23 | 2015-02-17 | The Coca-Cola Company | High-potency sweetener composition with glucosamine and compositions sweetened therewith |
| US8377491B2 (en) * | 2005-11-23 | 2013-02-19 | The Coca-Cola Company | High-potency sweetener composition with vitamin and compositions sweetened therewith |
| US8993027B2 (en) * | 2005-11-23 | 2015-03-31 | The Coca-Cola Company | Natural high-potency tabletop sweetener compositions with improved temporal and/or flavor profile, methods for their formulation, and uses |
| US8956678B2 (en) * | 2005-11-23 | 2015-02-17 | The Coca-Cola Company | High-potency sweetener composition with preservative and compositions sweetened therewith |
| US8945652B2 (en) * | 2005-11-23 | 2015-02-03 | The Coca-Cola Company | High-potency sweetener for weight management and compositions sweetened therewith |
| US8367138B2 (en) * | 2005-11-23 | 2013-02-05 | The Coca-Cola Company | Dairy composition with high-potency sweetener |
| US20070116822A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-potency sweetener composition with saponin and compositions sweetened therewith |
| KR20080071606A (ko) * | 2005-11-23 | 2008-08-04 | 더 코카콜라 컴파니 | 시간 특성 및/또는 향미 특성이 개선된 인공 감미료조성물과 이들의 제제 방법 및 용도 |
| US20070116839A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
| US8940350B2 (en) * | 2005-11-23 | 2015-01-27 | The Coca-Cola Company | Cereal compositions comprising high-potency sweeteners |
| US20070116825A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Confection with High-Potency Sweetener |
| US20070116829A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Pharmaceutical Composition with High-Potency Sweetener |
| US8435587B2 (en) * | 2005-11-23 | 2013-05-07 | The Coca-Cola Company | High-potency sweetener composition with long-chain primary aliphatic saturated alcohol and compositions sweetened therewith |
| US8524303B2 (en) * | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with phytosterol and compositions sweetened therewith |
| US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
| US8940351B2 (en) * | 2005-11-23 | 2015-01-27 | The Coca-Cola Company | Baked goods comprising high-potency sweetener |
| US9101160B2 (en) * | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| US20070116831A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Dental Composition with High-Potency Sweetener |
| US20070134391A1 (en) * | 2005-11-23 | 2007-06-14 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith |
| US8524304B2 (en) * | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith |
| US8512789B2 (en) * | 2005-11-23 | 2013-08-20 | The Coca-Cola Company | High-potency sweetener composition with dietary fiber and compositions sweetened therewith |
| US20070116800A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Chewing Gum with High-Potency Sweetener |
| US8435588B2 (en) * | 2005-11-23 | 2013-05-07 | The Coca-Cola Company | High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith |
| KR101385710B1 (ko) * | 2005-11-23 | 2014-04-17 | 더 코카콜라 컴파니 | 시간 특성 및/또는 향미 특성이 개선된 천연 고효능 감미료 조성물, 그 제제 방법 및 용도 |
| US20070116833A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition with Calcium and Compositions Sweetened Therewith |
| US9144251B2 (en) * | 2005-11-23 | 2015-09-29 | The Coca-Cola Company | High-potency sweetener composition with mineral and compositions sweetened therewith |
| US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
| US9101161B2 (en) * | 2006-11-02 | 2015-08-11 | The Coca-Cola Company | High-potency sweetener composition with phytoestrogen and compositions sweetened therewith |
| US8017168B2 (en) * | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| US10348730B2 (en) * | 2015-12-28 | 2019-07-09 | International Business Machines Corporation | Reducing complexities of authentication and authorization for enterprise web-based social applications |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1242622B (de) | 1964-05-30 | 1967-06-22 | Pfizer G M B H | Verfahren zur Herstellung der Molekuelverbindung von 1-Phenyl-2, 3-dimethylpyrazolon-(5) mit Cyclohexylsulfaminsaeure |
| GB1297261A (enExample) | 1969-01-13 | 1972-11-22 | ||
| DE2453063A1 (de) | 1974-11-08 | 1976-05-13 | Hoechst Ag | Verfahren zur herstellung von acetoacetamid-n-sulfofluorid |
| US4362730A (en) | 1980-08-25 | 1982-12-07 | Heinrich Mack Nachf. Chem-Pharm. Fabrik | Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein |
| DE3410439A1 (de) | 1984-03-22 | 1985-09-26 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-on-2,2-dioxid und dessen nichttoxischen salzen sowie der dabei als zwischenprodukt(e) auftretenden acetoacetamind-n-sulfonsaeure(salze) |
| IT1237517B (it) * | 1989-11-24 | 1993-06-08 | Magis Farmaceutici | Composti ottenuti per complessazione della pentossifillina con ciclodeciclodestrine, loro preparazione e relative composizioni farmaceutiche |
| HUP9701293A3 (en) | 1997-07-25 | 1999-08-30 | Chinoin Gyogyszer Es Vegyeszet | New salts without unsavoury taste and pharmaceutical compositions containing them |
| US5976602A (en) | 1998-05-06 | 1999-11-02 | Nutrinova, Inc. | Method of formulating acidified cola beverages and compositions so formulated |
| WO2000007541A2 (de) | 1998-07-31 | 2000-02-17 | Aventis Pharma Deutschland Gmbh | Verwendung von xanthinderivaten zur behandlung von erektionsstörungen |
| DE19834604A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Marion Roussel De Gmbh | Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen |
| JP2003525855A (ja) | 1998-08-27 | 2003-09-02 | ブリストル−マイヤーズ スクイブ カンパニー | 新規な薬剤塩形態 |
| DE10013259A1 (de) | 2000-03-17 | 2001-09-20 | Nutrinova Gmbh | Acesulfam-Metall-Komplexe Verfahren zu ihrer Herstellung und ihre Verwendung |
-
2001
- 2001-06-25 DE DE10130504A patent/DE10130504B4/de not_active Expired - Fee Related
-
2002
- 2002-06-07 US US10/165,399 patent/US6849623B2/en not_active Expired - Fee Related
- 2002-06-14 EP EP02013464A patent/EP1270573B1/de not_active Expired - Lifetime
- 2002-06-14 DE DE50200914T patent/DE50200914D1/de not_active Expired - Fee Related
- 2002-06-24 JP JP2002183006A patent/JP2003026665A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20030008865A1 (en) | 2003-01-09 |
| DE50200914D1 (de) | 2004-10-07 |
| DE10130504B4 (de) | 2005-02-03 |
| DE10130504A1 (de) | 2003-01-09 |
| EP1270573A1 (de) | 2003-01-02 |
| EP1270573B1 (de) | 2004-09-01 |
| US6849623B2 (en) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003026665A (ja) | 改善された味覚を有するキサンチン−およびフェナゾン−アセスルファム−ｈ−錯塩、その製造及び使用法 | |
| RU2292876C2 (ru) | Фармацевтические соли трамадола | |
| EP1219182A2 (de) | Salze von L-Aminosäuren mit verbessertem Geschmack und ihre Herstellung | |
| US20010029959A1 (en) | Nicotine salts having improved taste, process for their preparation and their use | |
| JP2003508429A5 (enExample) | ||
| JP2005516009A (ja) | 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品 | |
| AU599034B2 (en) | Furosemide salts | |
| CA3190332A1 (en) | Trientine tetrahydrochloride and a method of preparation and a pharmaceutical composition thereof | |
| EP1622899B1 (en) | Pioglitazone sulfate, pharmaceutical compositions and their use | |
| EP4606798A1 (en) | Benzoisothiazole compound, and pharmaceutical composition and use thereof | |
| HU187626B (en) | Process for preparing vincamine saccharinate | |
| TWI222878B (en) | Pharmaceutical compositions | |
| CN1128999A (zh) | 杂环化合物 | |
| EP1003557A2 (en) | New salts with beneficial organoleptic properties | |
| JP2003026678A (ja) | 向上された味を有するカフェイン錯体、それの製造法及び使用法 | |
| EP0923932B1 (en) | Composition containing antitumor agent | |
| KR101175120B1 (ko) | 나테글리니드 함유 제제 | |
| RU2240996C1 (ru) | Цис-диамино (2,2,6,6,-тетраметилпиперид-4-ил)тетрахлорплатина (iv) дигидрат и способ его получения | |
| JPS5857431B2 (ja) | 脳血管拡張剤２，３−置換−４−複素環状アミノスルホニルベンゼンスルホンアミドの製法 | |
| KR20230172013A (ko) | 트리엔틴 테트라하이드로클로라이드 및 이의 제조 방법 및 이의 조성물 | |
| RU2050848C1 (ru) | Способ маскировки вкуса тимола в лекарственных формах | |
| RU2536683C1 (ru) | 6-метил-1-(1-оксотиетан-3-ил)урацил, обладающий гипотензивной активностью | |
| JPH06298737A (ja) | ピラゾール誘導体 | |
| EP1640374A1 (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
| HK1093197B (en) | Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050328 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060720 |